602 related articles for article (PubMed ID: 17033748)
1. Enterobacter bacteremia: Clinical features, risk factors for multiresistance and mortality in a Chinese University Hospital.
Ye Y; Li JB; Ye DQ; Jiang ZJ
Infection; 2006 Oct; 34(5):252-7. PubMed ID: 17033748
[TBL] [Abstract][Full Text] [Related]
2. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and risk factors for attributable mortality in Enterobacter cloacae bacteremia.
Lin YC; Chen TL; Ju HL; Chen HS; Wang FD; Yu KW; Liu CY
J Microbiol Immunol Infect; 2006 Feb; 39(1):67-72. PubMed ID: 16440126
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and predictors of mortality in patients with Enterobacter aerogenes bacteremia.
Chang EP; Chiang DH; Lin ML; Chen TL; Wang FD; Liu CY
J Microbiol Immunol Infect; 2009 Aug; 42(4):329-35. PubMed ID: 19949757
[TBL] [Abstract][Full Text] [Related]
5. The clinical relevance of Enterobacter infections.
Shlaes DM
Clin Ther; 1993; 15 Suppl A():21-8. PubMed ID: 8513457
[TBL] [Abstract][Full Text] [Related]
6. Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii.
Deal EN; Micek ST; Ritchie DJ; Reichley RM; Dunne WM; Kollef MH
Pharmacotherapy; 2007 Feb; 27(2):191-9. PubMed ID: 17253909
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
[TBL] [Abstract][Full Text] [Related]
8. [Nosocomial bacteremia caused by Enterobacter spp.: epidemiology and prognostic factors].
Peña C; Pujol M; Pallarés R; Cisnal M; Ariza J; Gudiol F
Enferm Infecc Microbiol Clin; 1993 Oct; 11(8):424-8. PubMed ID: 8260514
[TBL] [Abstract][Full Text] [Related]
9. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and risk factors for mortality in Morganella morganii bacteremia.
Lee IK; Liu JW
J Microbiol Immunol Infect; 2006 Aug; 39(4):328-34. PubMed ID: 16926980
[TBL] [Abstract][Full Text] [Related]
11. Enterobacter bacteremia in the community hospital.
Haddy RI; Cecil ML; Norris LL; Markert RJ
J Fam Pract; 1991 Jun; 32(6):601-6. PubMed ID: 2040885
[TBL] [Abstract][Full Text] [Related]
12. Enterobacter bacteremia.
Gupta N; Aparna ; Choudhary U; Garg N; Arora DR
J Assoc Physicians India; 2003 Jul; 51():669-72. PubMed ID: 14621034
[TBL] [Abstract][Full Text] [Related]
13. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
14. Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with enterobacter bacteremia.
Lee SO; Kim YS; Kim BN; Kim MN; Woo JH; Ryu J
Eur J Clin Microbiol Infect Dis; 2002 Aug; 21(8):577-81. PubMed ID: 12226687
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of clinical and microbiological aspects of Klebsiella oxytoca bacteremia over a 10-year period.
Kim BN; Ryu J; Kim YS; Woo JH
Eur J Clin Microbiol Infect Dis; 2002 Jun; 21(6):419-26. PubMed ID: 12111596
[TBL] [Abstract][Full Text] [Related]
16. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay.
Sostarich AM; Zolldann D; Haefner H; Luetticken R; Schulze-Roebecke R; Lemmen SW
Infection; 2008 Feb; 36(1):31-5. PubMed ID: 18231721
[TBL] [Abstract][Full Text] [Related]
17. Fusobacterium bacteremia: clinical significance and outcomes.
Su CP; Huang PY; Yang CC; Lee MH
J Microbiol Immunol Infect; 2009 Aug; 42(4):336-42. PubMed ID: 19949758
[TBL] [Abstract][Full Text] [Related]
18. Group A streptococcal bacteremia: outcome and prognostic factors.
Vallalta Morales M; Soriano Navarro CJ; Salavert Lletí M; Montero Alonso M; Pérez Bellés C; López Aldeguer J; Otero MC; Gobernado Serrano M
Rev Esp Quimioter; 2006 Dec; 19(4):367-75. PubMed ID: 17235407
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study of prognostic and risk factors for mortality in polymicrobial bacteremia-fungemia in a university hospital: development over 10 years].
Ruiz-Giardín JM; Noguerado A; Pizarro A; Méndez J; La Hulla F; Fernández M; Hernández F; San Martín JV; Hernández I; Alvarez J; Salvanes F
Enferm Infecc Microbiol Clin; 2002 Nov; 20(9):435-42. PubMed ID: 12425877
[TBL] [Abstract][Full Text] [Related]
20. Nosocomial and community-acquired Enterobacter cloacae bloodstream infection: risk factors for and prevalence of SHV-12 in multiresistant isolates in a medical centre.
Liu CP; Wang NY; Lee CM; Weng LC; Tseng HK; Liu CW; Chiang CS; Huang FY
J Hosp Infect; 2004 Sep; 58(1):63-77. PubMed ID: 15350716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
